Evidence map›Paper›PMID 38727008›Full record

ArticleBiomedical chromatography : BMC2024

Development and validation of HPLC-ultraviolet method for quantitative determination of pritelivir in human placental perfusion medium.

Xiaoming Wang, Svetlana Patrikeeva, Tatiana Nanovskaya, Valentina Bryant

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical chromatography : BMC, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiaoming WangMaternal-Fetal Pharmacology and Bio-Development Laboratories, Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, Texas, USA.ORCID https://orcid.org/0000-0002-6018-568X
Svetlana PatrikeevaMaternal-Fetal Pharmacology and Bio-Development Laboratories, Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, Texas, USA.
Tatiana NanovskayaMaternal-Fetal Pharmacology and Bio-Development Laboratories, Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, Texas, USA.
Valentina BryantMaternal-Fetal Pharmacology and Bio-Development Laboratories, Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, Texas, USA.

Funding

Human placental biodisposition of novel antiherpesviral drugs, amenamevir and pritelivir, using ex vivo and in vitro experimental modelsR01HD107428 · NICHD · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRYANT, VALENTINA FOKINA · 2022 to 2024
$1.2M
NICHD NIH HHS R01 HD107428
6 · The paper itself

Abstract

A simple and reliable HPLC-ultraviolet (HPLC-UV) method was developed and validated for the quantification of pritelivir in the samples of medium from the experiments utilizing the ex vivo technique of dual perfusion of the human placental lobule. Phenacetin was used as an internal standard (IS) in our HPLC-UV method. Chromatographic separation of pritelivir and phenacetin was achieved on a Waters Symmetry C

Indexed as

Limit of DetectionPlacentaChromatography, High Pressure LiquidFemaleHumansLinear ModelsPerfusionPregnancyReproducibility of ResultsSpectrophotometry, UltravioletSulfonamidesSulfonamidesHPLC‐UVhuman placentapritelivirquantitative

Identifiers

PMID38727008
PMCPMC11262560

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.